A Phase I, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Oral Dose Study of SGM-1019 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 09 Apr 2018
At a glance
- Drugs SGM 1019 (Primary)
- Indications Inflammatory bowel diseases
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Second Genome
- 09 Apr 2018 Results (safety and pharmacodynamics) presented in a Second Genome media release.
- 09 Apr 2018 According to a Second Genome media release, preclinical data and results from this trial will be presented at the European Association for the Study of the Liver (EASL) International Liver Congress 2018 (on Friday, 13 Apr 2018).
- 20 Jan 2015 New trial record